Fleroxacin

	WikiDoc Resources for Fleroxacin
Articles
Most recent articles on Fleroxacin Most cited articles on Fleroxacin Review articles on Fleroxacin Articles on Fleroxacin in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Fleroxacin Images of Fleroxacin Photos of Fleroxacin Podcasts & MP3s on Fleroxacin Videos on Fleroxacin
Evidence Based Medicine
Cochrane Collaboration on Fleroxacin Bandolier on Fleroxacin TRIP on Fleroxacin
Clinical Trials
Ongoing Trials on Fleroxacin at Clinical Trials.gov Trial results on Fleroxacin Clinical Trials on Fleroxacin at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Fleroxacin NICE Guidance on Fleroxacin NHS PRODIGY Guidance FDA on Fleroxacin CDC on Fleroxacin
Books
Books on Fleroxacin
News
Fleroxacin in the news Be alerted to news on Fleroxacin News trends on Fleroxacin
Commentary
Blogs on Fleroxacin
Definitions
Definitions of Fleroxacin
Patient Resources / Community
Patient resources on Fleroxacin Discussion groups on Fleroxacin Patient Handouts on Fleroxacin Directions to Hospitals Treating Fleroxacin Risk calculators and risk factors for Fleroxacin
Healthcare Provider Resources
Symptoms of Fleroxacin Causes & Risk Factors for Fleroxacin Diagnostic studies for Fleroxacin Treatment of Fleroxacin
Continuing Medical Education (CME)
CME Programs on Fleroxacin
International
Fleroxacin en Espanol Fleroxacin en Francais
Business
Fleroxacin in the Marketplace Patents on Fleroxacin
Experimental / Informatics
List of terms related to Fleroxacin

Fleroxacin
Clinical data
AHFS/Drugs.com	International Drug Names
ATC code	J01MA08 (WHO) ;
Identifiers
	IUPAC name 6,8-Difluoro-1-(2-fluoroethyl)-7-(4-methylpiperazin-1-yl)-4-oxoquinoline-3-carboxylic acid;
CAS Number	79660-72-3 ;
PubChem CID	3357;
DrugBank	DB04576 ;
ChemSpider	21112717 ;
UNII	N804LDH51K;
KEGG	D01716 ;
ChEMBL	ChEMBL6273 ;
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
Formula	C17H18F3N3O3
Molar mass	369.34 g/mol
3D model (JSmol)	Interactive image;
	SMILES CN1CCN(CC1)C2=C(C=C3C(=C2F)N(C=C(C3=O)C(=O)O)CCF)F;
	InChI InChI=1S/C17H20F3N3O3/c1-21-4-6-22(7-5-21)15-12(19)8-10-14(13(15)20)23(3-2-18)9-11(16(10)24)17(25)26/h8,11H,2-7,9H2,1H3,(H,25,26) ; Key:NXMDNIYZQTTZFR-UHFFFAOYSA-N ;
(what is this?) (verify)

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Fleroxacin is a quinolone.^[1] It is sold under the brand names Quinodis and Megalocin.

Mechanism of action

Fleroxacin is a bactericidal drug that inhibits bacterial DNA gyrase and topoisomerase IV. Like other quinolones and fluoroquinolones the compound eradicates bacteria by interfering with DNA replication (bacterial DNA replication, transcription, repair and recombination).^[2]^[3]^[4]^[4] Fleroxacin is active against many Gram-positive and Gram-negative bacteria. It is especially active against Shigella species., Salmonella sp., Escherichia coli, Branhamella catarrhalis, Haemophilus influenzae, Neisseria gonorrhoeae, Yersinia enterocolitica, Serratia marcescens, Staphylococcus aureus, Pseudomonas aeruginosa.^[5]^[6]

Pharmacokinetics

After oral administration fleroxacin is rapidly and well absorbed from the gastrointestinal tract and shows a good bioavailability. The antibiotic is widely distributed throughout the body and in the different biological tissues. In many biologic specimens the levels of fleroxacin are similar to those in plasma, but in bile, nasal secretions, seminal fluid, lung, bronchial mucosa, and ovaries, the drug concentrations are 2-3 times higher than those in plasma.^[7] The serum elimination half-life, in subjects with normal renal function, is relatively long (9-12 hours), which permits once-daily dosing. Approximately the urinary excretion is 38% of an orally administered dose within 48 h, and in urine is possible detect 8.6% of the N-demethyl metabolite and 4.4% of the N-oxide metabolite. Fleroxacin can penetrate into milk of nursing women. As quinolones are known to induce arthropathy in juvenile animals, administration of the drug to breast-feeding women cannot be allowed.^[8]

Medical uses

Fleroxacin is effective in the treatment of a wide variety of infections, particularly uncomplicated cystitis in women, acute uncomplicated pyelonephritis, gonorrhea, bacterial enteritis, traveler's diarrhea, respiratory tract infections ( including exacerbation of chronic bronchitis).^[9]^[10]

Adverse effects

In treated patients the most common adverse reactions are gastrointestinal, including dyspepsia, nausea, vomiting, flatulence, abdominal pain, diarrhea and sometimes constipation. Also common disorders affecting the skin (itching, urticaria, rash, phototoxicity and photosensitivity)^[11] and central nervous system (dizziness, headache, tremor, paresthesia, impaired sense of taste and smell), psychiatric disorders (alteration of the sleep-wake cycle state of anxiety, depression, hallucinations and nightmares).^[12]^[13] Fleroxacin and other fluoroquinolones, are known to trigger seizures or lower the seizure threshold, due to their inhibitory activity on GABA receptor binding. The antibiotic should not be administered to patients with epilepsy or a personal history of previous convulsive attacks as may promote the onset of these disorders.^[14]^[15]

Contraindications

Fleroxacin is contraindicated in patients with a history of hypersensitivity to the substance or any other member of the quinolone class, or any component of the medicine. Fleroxacin, like other fluoroquinolones, can cause degenerative changes in weightbearing joints of young animals. The antibiotic should only be used in children when the expected benefits are outweigh the risks.

References

↑ Rubinstein, E. (2001). "History of quinolones and their side effects". Chemotherapy. 47 (Suppl 3): 3–8, discussion 44–8. doi:10.1159/000057838. PMID 11549783.
↑ Asahina Y, Iwase K, Iinuma F, Hosaka M, Ishizaki T (May 2005). "Synthesis and antibacterial activity of 1-(2-fluorovinyl)-7-substituted-4-quinolone-3-carboxylic acid derivatives, conformationally restricted analogues of fleroxacin". Journal of Medicinal Chemistry. 48 (9): 3194–202. doi:10.1021/jm0402061. PMID 15857125. Retrieved 2014-09-26.
↑ Yoshida H, Nakamura M, Bogaki M, Ito H, Kojima T, Hattori H, Nakamura S (April 1993). "Mechanism of action of quinolones against Escherichia coli DNA gyrase". Antimicrobial Agents and Chemotherapy. 37 (4): 839–45. doi:10.1128/aac.37.4.839. PMC 187778. PMID 8388200. Retrieved 2014-09-26.
↑ ^4.0 ^4.1 Wolfson JS, Hooper DC (October 1985). "The fluoroquinolones: structures, mechanisms of action and resistance, and spectra of activity in vitro". Antimicrobial Agents and Chemotherapy. 28 (4): 581–6. doi:10.1128/aac.28.4.581. PMC 180310. PMID 3000292. Retrieved 2014-09-26.
↑ Chin NX, Brittain DC, Neu HC (April 1986). "In vitro activity of Ro 23-6240, a new fluorinated 4-quinolone". Antimicrobial Agents and Chemotherapy. 29 (4): 675–80. doi:10.1128/aac.29.4.675. PMC 180465. PMID 3085584. Retrieved 2014-09-26.
↑ Hirai K, Aoyama H, Hosaka M, Oomori Y, Niwata Y, Suzue S, Irikura T (June 1986). "In vitro and in vivo antibacterial activity of AM-833, a new quinolone derivative". Antimicrobial Agents and Chemotherapy. 29 (6): 1059–66. doi:10.1128/aac.29.6.1059. PMC 180500. PMID 2942103. Retrieved 2014-09-26.
↑ Weidekamm E, Portmann R (March 1993). "Penetration of fleroxacin into body tissues and fluids". Am. J. Med. 94 (3A): 75S–80S. PMID 8452186. |access-date= requires |url= (help)
↑ Dan M, Weidekamm E, Sagiv R, Portmann R, Zakut H (February 1993). "Penetration of fleroxacin into breast milk and pharmacokinetics in lactating women". Antimicrobial Agents and Chemotherapy. 37 (2): 293–6. doi:10.1128/aac.37.2.293. PMC 187655. PMID 8452360. Retrieved 2014-09-26.
↑ Naber KG (March 1996). "Fleroxacin overview". Chemotherapy. 42 Suppl 1: 1–9. doi:10.1159/000239485. PMID 8861529. |access-date= requires |url= (help)
↑ Balfour JA, Todd PA, Peters DH (May 1995). "Fleroxacin. A review of its pharmacology and therapeutic efficacy in various infections". Drugs. 49 (5): 794–850. doi:10.2165/00003495-199549050-00010. PMID 7601015. |access-date= requires |url= (help)
↑ Kimura M, Kawada A, Kobayashi T, Hiruma M, Ishibashi A (January 1996). "Photosensitivity induced by fleroxacin". Clin. Exp. Dermatol. 21 (1): 46–7. doi:10.1046/j.1365-2230.1996.d01-158.x. PMID 8689769. |access-date= requires |url= (help)
↑ Bowie WR, Willetts V, Jewesson PJ (October 1989). "Adverse reactions in a dose-ranging study with a new long-acting fluoroquinolone, fleroxacin". Antimicrob. Agents Chemother. 33 (10): 1778–82. doi:10.1128/aac.33.10.1778. PMC 172754. PMID 2511802. Retrieved 2014-09-26.
↑ Geddes AM (March 1993). "Safety of fleroxacin in clinical trials". Am. J. Med. 94 (3A): 201S–203S. PMID 8452181. |access-date= requires |url= (help)
↑ Taga F, Kobayashi F, Saito S, Ooie T, Kawahara F, Uchida H, Shimada J, Hori S, Sakai O (August 1990). "Possibility for induction of convulsion by fleroxacin and its disposition in the central nervous system in animals". Arzneimittel-Forschung. 40 (8): 900–4. PMID 2173611. |access-date= requires |url= (help)
↑ Kimura M, Fujiyama J, Nagai A, Hirayama M, Kuriyama M (September 1998). "[Encephalopathy induced by fleroxacin in a patient with Machado-Joseph disease]". Rinshō Shinkeigaku = Clinical Neurology (in Japanese). 38 (9): 846–8. PMID 10078039. |access-date= requires |url= (help)

Template:QuinoloneAntiBiotics

[1] Rubinstein, E. (2001). "History of quinolones and their side effects". Chemotherapy. 47 (Suppl 3): 3–8, discussion 44–8. doi:10.1159/000057838. PMID 11549783.

[pmid15857125-2] Asahina Y, Iwase K, Iinuma F, Hosaka M, Ishizaki T (May 2005). "Synthesis and antibacterial activity of 1-(2-fluorovinyl)-7-substituted-4-quinolone-3-carboxylic acid derivatives, conformationally restricted analogues of fleroxacin". Journal of Medicinal Chemistry. 48 (9): 3194–202. doi:10.1021/jm0402061. PMID 15857125. Retrieved 2014-09-26.

[pmid8388200-3] Yoshida H, Nakamura M, Bogaki M, Ito H, Kojima T, Hattori H, Nakamura S (April 1993). "Mechanism of action of quinolones against Escherichia coli DNA gyrase". Antimicrobial Agents and Chemotherapy. 37 (4): 839–45. doi:10.1128/aac.37.4.839. PMC 187778. PMID 8388200. Retrieved 2014-09-26.

[pmid3000292-4] 4.0 ^4.1 Wolfson JS, Hooper DC (October 1985). "The fluoroquinolones: structures, mechanisms of action and resistance, and spectra of activity in vitro". Antimicrobial Agents and Chemotherapy. 28 (4): 581–6. doi:10.1128/aac.28.4.581. PMC 180310. PMID 3000292. Retrieved 2014-09-26.

[pmid3085584-5] Chin NX, Brittain DC, Neu HC (April 1986). "In vitro activity of Ro 23-6240, a new fluorinated 4-quinolone". Antimicrobial Agents and Chemotherapy. 29 (4): 675–80. doi:10.1128/aac.29.4.675. PMC 180465. PMID 3085584. Retrieved 2014-09-26.

[pmid2942103-6] Hirai K, Aoyama H, Hosaka M, Oomori Y, Niwata Y, Suzue S, Irikura T (June 1986). "In vitro and in vivo antibacterial activity of AM-833, a new quinolone derivative". Antimicrobial Agents and Chemotherapy. 29 (6): 1059–66. doi:10.1128/aac.29.6.1059. PMC 180500. PMID 2942103. Retrieved 2014-09-26.

[pmid8452186-7] Weidekamm E, Portmann R (March 1993). "Penetration of fleroxacin into body tissues and fluids". Am. J. Med. 94 (3A): 75S–80S. PMID 8452186. |access-date= requires |url= (help)

[pmid8452360-8] Dan M, Weidekamm E, Sagiv R, Portmann R, Zakut H (February 1993). "Penetration of fleroxacin into breast milk and pharmacokinetics in lactating women". Antimicrobial Agents and Chemotherapy. 37 (2): 293–6. doi:10.1128/aac.37.2.293. PMC 187655. PMID 8452360. Retrieved 2014-09-26.

[pmid8861529-9] Naber KG (March 1996). "Fleroxacin overview". Chemotherapy. 42 Suppl 1: 1–9. doi:10.1159/000239485. PMID 8861529. |access-date= requires |url= (help)

[pmid7601015-10] Balfour JA, Todd PA, Peters DH (May 1995). "Fleroxacin. A review of its pharmacology and therapeutic efficacy in various infections". Drugs. 49 (5): 794–850. doi:10.2165/00003495-199549050-00010. PMID 7601015. |access-date= requires |url= (help)

[pmid8689769-11] Kimura M, Kawada A, Kobayashi T, Hiruma M, Ishibashi A (January 1996). "Photosensitivity induced by fleroxacin". Clin. Exp. Dermatol. 21 (1): 46–7. doi:10.1046/j.1365-2230.1996.d01-158.x. PMID 8689769. |access-date= requires |url= (help)

[pmid2511802-12] Bowie WR, Willetts V, Jewesson PJ (October 1989). "Adverse reactions in a dose-ranging study with a new long-acting fluoroquinolone, fleroxacin". Antimicrob. Agents Chemother. 33 (10): 1778–82. doi:10.1128/aac.33.10.1778. PMC 172754. PMID 2511802. Retrieved 2014-09-26.

[pmid8452181-13] Geddes AM (March 1993). "Safety of fleroxacin in clinical trials". Am. J. Med. 94 (3A): 201S–203S. PMID 8452181. |access-date= requires |url= (help)

[pmid2173611-14] Taga F, Kobayashi F, Saito S, Ooie T, Kawahara F, Uchida H, Shimada J, Hori S, Sakai O (August 1990). "Possibility for induction of convulsion by fleroxacin and its disposition in the central nervous system in animals". Arzneimittel-Forschung. 40 (8): 900–4. PMID 2173611. |access-date= requires |url= (help)

[pmid10078039-15] Kimura M, Fujiyama J, Nagai A, Hirayama M, Kuriyama M (September 1998). "[Encephalopathy induced by fleroxacin in a patient with Machado-Joseph disease]". Rinshō Shinkeigaku = Clinical Neurology (in Japanese). 38 (9): 846–8. PMID 10078039. |access-date= requires |url= (help)

[1]

[2]

[3]

[4]

[5]

[6]

[7]

[8]

[9]

[10]

[11]

[12]

[13]

[14]

[15]